EU: marketing authorisation for boar taint vaccine is near

24-04-2009 | |

It is expected that in the coming two to three months, EU marketing authorisation will be granted for Improvac, a vaccine to control boar taint.

The vaccine, produced by Pfizer Animal Health, received a positive opinion of the Committee for Medicinal Products for Veterinary Use (CVMP) last month. Normally, it takes another 90 days from that moment before official authorisation is granted.

The two-shot vaccine causes an immunological suppression of testicular function, which removes the occurrence of boar taint and thus takes away the necessity to castrate male piglets. In addition, entire piglets grow better than castrates.

The committee recommended “to grant a marketing authorisation for the veterinary medicinal product Improvac a solution for injection with min. 300 μg per 2 ml dose, intended as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty.”

The committee recommended “use with a safety vaccinator with a dual safety system providing a needle guard and a mechanism to prevent accidental operation of the trigger.” This is to prevent effects after accidental self-injection.

Detailed conditions for the use of this product will be described in the Summary of Product Characteristics (SPC) which will be published in the European Public Assessment Report (EPAR) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Related website
• Pfizer Animal Health